Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...

In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs by partnering with KeyBioscience in 2017. At one time, the Big Pharma was ...

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.

Eli Lilly & Company Chairman and CEO Dave Ricks sheds light on growth and success, the increase in weight loss drug ...

A US university has launched a prevention trial examining the use of Eli Lilly’s investigational remternetug in young adults to prevent further development of Alzheimer’s disease. Washington ...

Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s ...

a defining event in the early cascade of Alzheimer’s disease onset,” Dr. Mark Mintun, group vice president of neuroscience research and development at Lilly, said in the news release.